SEC Form 4 · accession 0001437749-16-028528
RESPONSE BIOMEDICAL CORP · RBM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter A. Thompson
Director
Period of report
Mar 24, 2016
Accepted (ET)
Mar 28, 2016 · 9:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000806888
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 24, 2016 | A | 37,058 | $0.00 | A | 96,884 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F3 | $0.85 | Mar 24, 2016 | A | 5,000 | A | — | Mar 23, 2026 | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1100% of the restricted share units vested on the date of grant. The expiration date for each of the restricted share units will be the earlier of three (3) years after the effective date or two (2) years following the reporting person's termination date. The reporting person has elected to defer receipt of the common stock underlying the restricted share units until a later date not to exceed the expiration date.
- F2Exercise prices shown are denominated in Canadian dollars.
- F3Subject to the reporting person's continued service as a director of the company through each vesting date, 100% of the shares subject to the option shall vest and become exercisable on March 24, 2017.